somewhat older article about another company worki

Quote:

---

PGS-N007 (Psoriasis BiPhasix™ CBD Topical Cream)
The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3 percent. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States. According to Global Data and the World Health Organization, the reported prevalence of psoriasis in countries ranges between 0.09% and 11.4%, making psoriasis a serious global problem with at least 100 million individuals affected worldwide.
Research has shown that CBD has potent anti-inflammatory properties suggesting that cannabinoids may be helpful for inflammation-related skin conditions like psoriasis and eczema. CBD, THC and other cannabinoids are anti-psoriasis agents. Under a psoriasis condition, skin cells are replaced every three to five days rather than the normal 30 days. This excessive and rapid growth of the epidermal layer of the skin generates red, itchy and scaly patches, which may be localized or completely cover the body. PGS-N007 will aim to treat psoriasis.
These products (PGS-N005, PGS-N007) will be registered as 'natural health products' for consumers, which enables a shorter development cycle and faster revenue generation opportunities than traditional pharmaceuticals that tend to be much more expensive and time-consuming to develop through extensive clinical trials.

---